Kenya Impact Research And Development Organization Clinical Research Site (K Irdo Crs)

K-IRDO Clinical Research Site (CRS) is the research division of Impact Research and Development Organization (IRDO), a national research institution registered in Kenya in 2003. The CRS is domiciled in Tuungane Hospital, Tom Mboya Estate, Kisumu. The CRS has successfully conducted over 30 studies (clinical, observational and socio-behavioral), published over 140 articles in peer-reviewed journals, and made over 100 presentations at local and international conferences. Our site has clinical, pharmacy, laboratory and management capacity to conduct Phase II, III and IV clinical trials, including Investigational New Drugs and devices, with a focus on: Women and Children’s Health, Infectious Diseases (HIV, Malaria, Hepatitis, STIs, TB, etc.), NCDs (Diabetes, Cancers and Cardiovascular diseases), Others (Allergy, Gastroenterology, Hematology including sickle cell disease). The trial site has a dedicated team of 36 staff (1 principal investigator, 3 medical doctors, 6 nursing officers, 3 pharmacists, 5 laboratory technologists, 1 clinical officer, 6 research assistants, 5 field staff, 2 data-cum-IT officers, 2 regulatory affairs officers, 1 QA/QC officer, 1 study coordinator), with another 51 staff conducting studies in out-stations. There are nine ongoing studies, including a COVID-19 vaccine trial: Solidarity Trial Vaccines: An international randomized trial of candidate vaccines against COVID-19, which is a double blind, placebo controlled phase 3 multisite trial sponsored by WHO through Kenya AIDS Vaccine Initiative and Kenya Ministry of Health (Feb 2022 – Apr 2024). The study is in its follow up phase having successfully enrolled 500 participants at the site, with a current retention rate of 99%. The primary aim of the trial is to evaluate the safety and efficacy of candidate vaccines for prevention of COVID-19 infections.